World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
34654
World Ranking
18615
National Ranking
620

Josy Reiffers publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Josy Reiffers sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 410 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Josy Reiffers D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Josy Reiffers sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Josy Reiffers is affiliated with the Centre national de la recherche scientifique (CNRS) in France. Their work is linked to this prominent French research institution, which supports a wide range of scientific disciplines across multiple fields of study.

Although there is no detailed listing of Josy Reiffers' publications or frequent co-authors available, their connection with CNRS suggests involvement in rigorous academic research and collaboration within the scientific community.

The profile does not provide specific data on the main fields of study, subfields, or primary research topics associated with Josy Reiffers. Similarly, information on recent papers, book publications, or frequent publication venues has not been disclosed.

No awards or honors are recorded for Josy Reiffers in the provided data, and there is no indication that the scientist is deceased.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

    François-Xavier Mahon;Delphine Réa;Joëlle Guilhot;François Guilhot

  • Noninvasive Ventilation in Immunosuppressed Patients with Pulmonary Infiltrates, Fever, and Acute Respiratory Failure

    Gilles Hilbert;Didier Gruson;Fréderic Vargas;Ruddy Valentino

  • Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

    François Xavier Mahon;Michael W. N. Deininger;Beate Schultheis;Jérome Chabrol

  • MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

    François-Xavier Mahon;Francis Belloc;Valérie Lagarde;Claudine Chollet

  • Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

    Stephane Picard;Karine Titier;Gabriel Etienne;Emmanuelle Teilhet

  • Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

    Philippe Rousselot;Francoise Huguet;Delphine Rea;Laurence Legros

  • Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

    Carlo Gambacorti-Passerini;Laura Antolini;Franois Xavier Mahon;Francois Guilhot

  • Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

    Philippe Rousselot;Aude Charbonnier;Pascale Cony-Makhoul;Philippe Agape

  • Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.

    G. Gahrton;H. Svensson;M. Cavo;J. Apperley

  • A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia

    Hervé Dombret;Claude Chastang;Pierre Fenaux;Josy Reiffers

  • Allogeneic bone marrow transplantation in multiple myeloma

    G Gahrton;S Tura;P Ljungman;C Belanger

  • Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

    Francesca Bonifazi;Antonio de Vivo;Gianantonio Rosti;François Guilhot

  • Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse.

    D Blaise;D Maraninchi;E Archimbaud;J Reiffers

  • Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia

    F Lacombe;F Durrieu;A Briais;P Dumain

  • Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.

    G Michel;G Socié;F Gebhard;F Bernaudin

  • Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

    Stéphanie Dulucq;Stéphane Bouchet;Béatrice Turcq;Eric Lippert

  • Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia.

    Reiffers J;Bernard P;David B;Vezon G

  • Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.

    C Sebban;E Lepage;J P Vernant;E Gluckman

Frequent Co-Authors

Mauricette Michallet
Mauricette Michallet University of Helsinki
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Eliane Gluckman
Eliane Gluckman Université Paris Cité
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Michel Attal
Michel Attal Janssen (Belgium)
Pierre Bordigoni
Pierre Bordigoni Boston Children's Hospital
Myriam Labopin
Myriam Labopin Université Paris Cité
Gérard Socié
Gérard Socié Université Paris Cité
Richard A. Larson
Richard A. Larson University of Chicago
Daniel Olive
Daniel Olive Aix-Marseille University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens the door to a diverse range of educational pathways beyond the traditional MD track. Many students consider healthcare management roles, and pursuing the best online healthcare administration degree can be a fast and flexible choice. These programs are ideal for those interested in leading healthcare organizations or managing hospital operations.

For registered nurses seeking advanced clinical roles, asn to np programs provide an efficient bridge from an associate degree to a nurse practitioner qualification. These bridge programs often cater to working professionals and are available in online formats for added convenience.

Nutrition is another popular and growing field. Students committed to promoting wellness and disease prevention may benefit from pursuing online degrees in nutrition. Such degrees can lead to careers as dietitians, nutritionists, and health educators.

Those aiming for upper-level positions in healthcare administration can look for cahme accredited master’s programs, which set the national standard for healthcare management education.

Best Scientists Citing Josy Reiffers

Recently Published Articles